A phase Ib study of a single priming dose of 177Lu-PSMA617 coupled with pembrolizumab in metastatic castration resistant prostate cancer (mCRPC)

被引：0

作者：

Aggarwal, R. ^{[1
]}

Trihy, L. ^{[2
]}

Hernandez Romero, E. ^{[2
]}

Sam, S. Luch ^{[1
]}

Rastogi, M. ^{[1
]}

De Kouchkovsky, I. ^{[3
]}

Small, E. J. ^{[4
]}

Feng, F. ^{[5
]}

Kwon, D. ^{[3
]}

Friedlander, T. ^{[3
]}

Borno, H. T. ^{[3
]}

Bose, R. ^{[6
]}

Chou, J. ^{[3
]}

Koshkin, V. S. ^{[7
]}

Desai, A. ^{[8
]}

Feng, S. ^{[2
]}

Angelidakis, A. ^{[2
]}

Johnson, M. S. ^{[9
]}

Fong, L. ^{[10
]}

Hope, T. ^{[11
]}

机构：

[1] Univ Calif San Francisco, Med Dept, Parnassus Campus, San Francisco, CA USA

[2] UCSF Univ Calif San Francisco, Canc Ctr, San Francisco, CA USA

[3] UCSF Univ Calif San Francisco, Med, San Francisco, CA USA

[4] UCSF Helen Diller Family Comprehens Canc Ctr, Comprehens Canc Ctr, San Francisco, CA USA

[5] UCSF Univ Calif San Francisco, Radiat Oncol, Parnassus Campus, San Francisco, CA USA

[6] UCSF Univ Calif San Francisco, Anat, San Francisco, CA USA

[7] UCSF Helen Diller Family Comprehens Canc Ctr, Div Med Oncol, San Francisco, CA USA

[8] Univ Calif San Francisco, Dept Med, San Francisco, CA USA

[9] UCSF Med Ctr Mission Bay, Genitourinary Oncol Dept, San Francisco, CA USA

[10] UCSF Diabet Teaching Ctr, Med Dept, San Francisco, CA USA

[11] UCSF Univ Calif San Francisco, Radiol, San Francisco, CA USA

来源：

ANNALS OF ONCOLOGY | 2022年 / 33卷 / 07期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1379P

引用

页码：S1173 / S1173

页数：1

共 50 条

[31] 177Lu-PSMA-617 Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer Patients with a Single Functioning Kidney
Zhang, Jingjing
Kulkarni, Harshad R.
Singh, Aviral
Schuchardt, Christiane
Niepsch, Karin
Langbein, Thomas
Baum, Richard P.
JOURNAL OF NUCLEAR MEDICINE, 2019, 60 (11) : 1579 - 1586
[32] Tolerability of [177Lu]Lu-PSMA-617 by treatment exposure in patients with metastatic castration-resistant prostate cancer (mCRPC): A VISION study subgroup analysis.
Tagawa, Scott T.
Armstrong, Andrew J.
Krause, Bernd J.
Herrmann, Ken
Rahbar, Kambiz
De Bono, Johann S.
Adra, Nabil
Desilvio, Michelle
Messmann, Richard
Holder, Geoffrey
Chi, Kim N.
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[33] 177Lu-PSMA-617 radioligand therapy in metastatic castration-resistant prostate cancer patients with a single functioning kidney
Zhang, Jingjing
Kulkarni, Harshad
Singh, Aviral
Schuchardt, Christiane
Niepsch, Karin
Langbein, Thomas
Baum, Richard
JOURNAL OF NUCLEAR MEDICINE, 2019, 60
[34] Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer
Sartor, Oliver
de Bono, Johann
Chi, Kim N.
Fizazi, Karim
Herrmann, Ken
Rahbar, Kambiz
Tagawa, Scott T.
Nordquist, Luke T.
Vaishampayan, Nitin
El-Haddad, Ghassan
Park, Chandler H.
Beer, Tomasz M.
Armour, Alison
Perez-Contreras, Wendy J.
DeSilvio, Michelle
Kpamegan, Euloge
Gericke, Germo
Messmann, Richard A.
Morris, Michael J.
Krause, Bernd J.
NEW ENGLAND JOURNAL OF MEDICINE, 2021, 385 (12): : 1091 - 1103
[35] Safety and response to177Lu-EB-PSMA-617 in patients with metastatic castration-resistant prostate cancer
Zang, Jie
Liu, Qingxing
Jacobson, Orit
Niu, Gang
Fan, Xinrong
Zhu, Zhaohui
Chen, Xiaoyuan
JOURNAL OF NUCLEAR MEDICINE, 2019, 60
[36] Intermittent Lu-177-PSMA-617 therapy of metastatic castration-resistant prostate cancer in early responders
Mader, Nicolai
Ngoc, Christina Nguyen
Baumgarten, Justus
Groener, Daniel
Davis, Karen
Wichert, Jennifer
Tselis, Nikolaos
Mandel, Philipp
Gruenwald, Frank
Sabet, Amir
JOURNAL OF NUCLEAR MEDICINE, 2020, 61
[37] Promising 177Lu-PSMA-617 Therapy Results in Patients with Metastatic Castration-Resistant Prostate Cancer
Brnjic, Antonio
Frye, Sarah
Botkin, Crystal
Osman, Medhat
JOURNAL OF NUCLEAR MEDICINE, 2021, 62
[38] Safety Analyses of the Phase 3 VISION Trial of [ 177 Lu]Lu-PSMA-617 in Patients with Metastatic Castration-resistant Prostate Cancer
Chi, Kim N.
Armstrong, Andrew J.
Krause, Bernd J.
Herrmann, Ken
Rahbar, Kambiz
de Bono, Johann S.
Adra, Nabil
Garje, Rohan
Michalski, Jeff M.
Kempel, Mette M.
Fizazi, Karim
Morris, Michael J.
Sartor, Oliver
Brackman, Marcia
Desilvio, Michelle
Wilke, Celine
Holder, Geoffrey
Tagawa, Scott T.
EUROPEAN UROLOGY, 2024, 85 (04) : 382 - 391
[39] [177Lu]-PSMA-617 radionuclide therapy in patients with metastatic castration-resistant prostate cancer
Rahbar, Kambiz
Ahmadzadehfar, Hojjat
Seifert, Robert
Boegemann, Martin
LANCET ONCOLOGY, 2018, 19 (08): : E371 - E371
[40] Safety and dosimetry of 177Lu-EB-PSMA617 in patients with metastatic castration-resistant prostate cancer
Zang, Jie
Wang, Hao
Liu, Qingxing
Jacobson, Orit
Niu, Gang
Zhu, Zhaohui
Chen, Xiaoyuan
JOURNAL OF NUCLEAR MEDICINE, 2018, 59

← 1 2 3 4 5 →